Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
AstraZeneca
Moodys
McKesson
Colorcon

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Desvenlafaxine succinate - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for desvenlafaxine succinate and what is the scope of freedom to operate?

Desvenlafaxine succinate is the generic ingredient in two branded drugs marketed by Actavis Labs Fl, Alembic Pharms Ltd, Casi Pharms Inc, Intellipharmaceutics, Lupin Ltd, Mylan, West-ward Pharms Int, Yichang Humanwell, Zydus Pharms, and Pf Prism Cv, and is included in eleven NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Desvenlafaxine succinate has sixty-eight patent family members in thirty-two countries.

There are sixteen drug master file entries for desvenlafaxine succinate. Twenty-two suppliers are listed for this compound.

Recent Clinical Trials for desvenlafaxine succinate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Seoul National University HospitalPhase 4
Korea Cancer Center HospitalPhase 4
Seoul National University Bundang HospitalPhase 4

See all desvenlafaxine succinate clinical trials

Recent Litigation for desvenlafaxine succinate

Identify potential future generic entrants

District Court Litigation
Case NameDate
Pfizer Inc. v. Apotex Inc.2012-06-22
Pfizer Inc. v. Mylan Pharmaceuticals Inc.2012-06-22
Pfizer Inc. v. Zydus Pharmaceuticals USA Inc.2012-06-22

See all desvenlafaxine succinate litigation

Medical Subject Heading (MeSH) Categories for desvenlafaxine succinate

US Patents and Regulatory Information for desvenlafaxine succinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes Yes   See Pricing   See Pricing Y   See Pricing
Mylan DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204095-001 Jun 29, 2015 AB RX No No   See Pricing   See Pricing   See Pricing
Alembic Pharms Ltd DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204003-003 Sep 14, 2018 AB RX No No   See Pricing   See Pricing   See Pricing
Actavis Labs Fl DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204065-001 Jul 29, 2016 AB RX No No   See Pricing   See Pricing   See Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Colorcon
AstraZeneca
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.